Find Grants for Native American & Tribal Governments

Find out if you qualify for verified grants for Native American & Tribal Governments. Discover your eligibility and key funding details for Native American & Tribal Governments from major foundations and government agencies.

Total Dollars Available
$ 100 Trillion

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-183

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-184

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-285

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-180

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-177

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required)

Deadline: October 15, 2027


Opportunity Number: PAR-25-178

Agency: National Institutes of Health

Open Date: November 26, 2024

Close Date: October 15, 2027

Status: Posted

CFDA Numbers: 93.242

HIV Prevention and Alcohol (R01 Clinical Trials Optional)

Deadline: May 7, 2026


Opportunity Number: PAS-25-208

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: May 7, 2026

Status: Posted

CFDA Numbers: 93.273

HIV Prevention and Alcohol (R34 Clinical Trials Optional)

Deadline: May 7, 2026


Opportunity Number: PAS-25-161

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: May 7, 2026

Status: Posted

CFDA Numbers: 93.273

Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R01 Clinical Trial Required)

Deadline: January 7, 2028


Opportunity Number: PAR-25-289

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.242

Navigator Emergency Department Diversion Models for Non-Urgent Mental Health Concerns (R34 Clinical Trial Required)

Deadline: January 7, 2028


Opportunity Number: PAR-25-288

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.242

New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Optional)

Deadline: May 7, 2027


Opportunity Number: PAR-25-279

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: May 7, 2027

Status: Posted

CFDA Numbers: 93.396, 93.866, 93.865, 93.286

New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)

Deadline: May 7, 2027


Opportunity Number: PAR-25-272

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: May 7, 2027

Status: Posted

CFDA Numbers: 93.866, 93.396, 93.865

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)

Deadline: January 7, 2027


Opportunity Number: PAR-25-159

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: January 7, 2027

Status: Posted

CFDA Numbers: 93.273

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

Deadline: November 17, 2026


Opportunity Number: PAR-25-158

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: November 17, 2026

Status: Posted

CFDA Numbers: 93.273

The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)

Deadline: January 7, 2028


Opportunity Number: PAR-25-292

Agency: National Institutes of Health

Open Date: November 25, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.866, 93.361, 93.393, 93.307, 93.399, 93.396, 93.279, 93.242

Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)

Deadline: December 23, 2027


Opportunity Number: RFA-HL-26-019

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: December 23, 2027

Status: Posted

CFDA Numbers: 93.837, 93.233, 93.839, 93.838

Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

Deadline: December 23, 2027


Opportunity Number: RFA-HL-26-016

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: December 23, 2027

Status: Posted

CFDA Numbers: 93.839, 93.233, 93.838, 93.837

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

Deadline: December 23, 2027


Opportunity Number: RFA-HL-26-020

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: December 23, 2027

Status: Posted

CFDA Numbers: 93.839, 93.233, 93.837, 93.838

Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

Deadline: December 23, 2027


Opportunity Number: RFA-HL-26-017

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: December 23, 2027

Status: Posted

CFDA Numbers: 93.839, 93.838, 93.233, 93.837

Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)

Deadline: December 23, 2027


Opportunity Number: RFA-HL-26-018

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: December 23, 2027

Status: Posted

CFDA Numbers: 93.839, 93.233, 93.838, 93.837

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

Deadline: January 7, 2028


Opportunity Number: PAR-25-281

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.242, 93.313

Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)

Deadline: January 7, 2028


Opportunity Number: PAR-25-282

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.242, 93.313

Occupational Safety and Health Training Project Grants (T03)

Deadline: October 26, 2028


Opportunity Number: RFA-OH-25-003

Agency: Centers for Disease Control and Prevention - ERA

Open Date: November 22, 2024

Close Date: October 26, 2028

Status: Posted

CFDA Numbers: 93.262

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Deadline: November 19, 2026


Opportunity Number: PAR-25-226

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: November 19, 2026

Status: Posted

CFDA Numbers: 93.242

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional)

Deadline: January 7, 2028


Opportunity Number: PAR-25-290

Agency: National Institutes of Health

Open Date: November 22, 2024

Close Date: January 7, 2028

Status: Posted

CFDA Numbers: 93.242

×

Request Grant Support from GTC 360° Advisors

Our expert team at GTC 360° Advisors can help develop your grant strategy, recruit partner organizations, write your full proposal, compile and manage your budgets, and help you submit a compelling and compliant proposal on time.